Full text not available from this repository.
(
recombinant activated factor VII (rFVIIa) is used off-label for massive bleeding. There is no convincing evidence of the benefits of this practice and the minimal effective dose is unknown. The aim of the study was to evaluate our in-house guideline recommending a low dose of 60 μg/kg for off-label use of rFVIIa.
Interest & Impact
Downloads
0 since deposited on 04 Oct 2013
0 in the past 12 months
Citations
5 Citations in Web of Science ®
6 Citations in Scopus
Search
in Google Scholar™
Services
Actions (login required)
 |
Edit item |
Item Type: |
Journal Article
(Original Article)
|
Division/Institute: |
04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic and Policlinic for Anaesthesiology and Pain Therapy
04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic of Intensive Care
04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > University Emergency Center
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory |
UniBE Contributor: |
Luginbühl, Martin, Regli, Bruno, Zimmermann, Heinz (B), Inderbitzin, Daniel, Lämmle, Bernhard, Alberio, Lorenzo |
ISSN: |
1424-7860 |
Publisher: |
EMH Schweizerischer Ärzteverlag |
Language: |
English |
Submitter: |
Jeannie Wurz
|
Date Deposited: |
04 Oct 2013 14:13 |
Last Modified: |
29 Mar 2023 23:32 |
Publisher DOI: |
10.4414/smw.2011.13213 |
PubMed ID: |
21735365 |
Web of Science ID: |
000292558000005 |
URI: |
https://boris.unibe.ch/id/eprint/3056 (FactScience: 206332) |
|
|
|
|
